

Halle (Saale), August 18<sup>th</sup>, 2009

### ***Press release of Scil Proteins GmbH***

#### **Boarding completed**

Henning Afflerbach appointed as Chief Business Officer for Scil Proteins

Halle (Saale), August 18<sup>th</sup>, 2009. Scil Proteins GmbH appoints Dr. Henning Afflerbach as Chief Business Officer (CBO) and completes the management board.

Before joining Scil Proteins, Dr. Afflerbach was responsible for business development at a number of different biotechnology companies including Peptor GmbH/Ltd (Rehovot/Erkrath), Develogen (Göttingen), and DIREVO Biotech (Cologne). At Scil Proteins he will concentrate on the commercialization of Scil Proteins unique Affilin<sup>®</sup> platform. In addition, he will continue the successful business activities of the Scil Proteins Group within the areas of protein production and process development.

“The Scil Proteins Group preeminently combines core competencies for Research & Development and Manufacturing of innovative biopharmaceutical products. Scil Proteins proprietary platform technologies together with the broad expertise in protein chemistry bear an outstanding potential for the generation and the commercialization of promising new biopharmaceuticals”, says CBO Henning Afflerbach.

“With the appointment of Dr. Afflerbach the management board is now complete. I am looking forward to work with such an experienced and powerful team”, adds CEO Ulrike Fiedler. In May Frank Ubags was appointed the company’s new CFO, replacing Christian Nafe, who joined the Scil-team in Munich.

#### ***About the persons:***

**Dr. Henning Afflerbach** has been holding different management positions within the biotechnology industry for more than 10 years. He was in charge of the business development of the companies Peptor GmbH/Ltd (Rehovot/Erkrath), Develogen (Göttingen), and DIREVO Biotech (Cologne). Afflerbach successfully conducted several multi-national negotiations on licensing with globally operating pharmaceutical and bio-technological companies. Before joining Scil Proteins, he was actively involved in the acquisition of Direvo Biotech by Bayer Healthcare AG.

**Frank Ubags** was CFO at Rhein Biotech (Maastricht, Düsseldorf). To begin with he was responsible for the initial public offering of the corporation as well as for several acquisitions of companies in Asia and South America. In 2002 he conducted the sale to Berna Biotech (Bern) and as CEO he was responsible for the sale of Rhein Biotech Düsseldorf to Dynavax (USA) in 2006. Later on he held

the post of CFO at Kiadis Pharma (Amsterdam, Montreal). Before joining Scil Proteins, he worked as an independent consultant for a short period of time.

***About Scil Proteins :***

**Scil Proteins** specializes in researching, developing and producing recombinant proteins. Scil Proteins is actively involved in two business areas: (1) Scil Proteins Pharma develops innovative bio-pharmaceutical products on the basis of the Affilin<sup>®</sup> technology, and (2) Scil Proteins Production produces recombinant proteins as a contract manufacturing organization for research, clinical studies and the market.

**About Affilin<sup>®</sup> Therapeutics:**

Scil Proteins Affilin<sup>®</sup> therapeutics platform has been designed for the rapid selection of novel pharmaceutical proteins with high specificity for disease relevant targets. Affilin<sup>®</sup> therapeutics are small, very stable and perfectly suited for penetration of diseased tissue and application in destabilizing milieu conditions. As such, Affilin<sup>®</sup> therapeutics enter indication areas where other more complex and less stable molecules remain ineffective.

Affilin<sup>®</sup> therapeutics are so called scaffold proteins derived from variations of the natural protein Ubiquitin, a protein with ubiquitous distribution pattern in the human body. Due to the high degree of sequence conservation of their scaffold Ubiquitin Affilin<sup>®</sup> therapeutics bear very low immunogenic potential and offer predictive immunogenicity screening in relevant animal models.

Scil Proteins proprietary Multi-Affilin<sup>®</sup> platform allows the precise modulation of pharmacokinetic parameters of Affilin<sup>®</sup> therapeutics resulting in serum half lives applicable for acute and chronic treatment settings. Scil Proteins Affilin<sup>®</sup> and Multi-Affilin<sup>®</sup> platforms are broadly patent protected for a comprehensive freedom to operate on multiple disease targets of choice.

Contact Scil Proteins GmbH:  
Dr. Ole Fuetterer  
Director of Business Development  
Heinrich-Damerow-Strasse 1

06120 Halle (Saale)  
Telephone: +49 (0) 3 45 478 03 03  
Fax: +49 (0) 3 45 478 03 01  
E-mail: [Ole.Fuetterer@scilproteins.com](mailto:Ole.Fuetterer@scilproteins.com)  
Internet: [www.scilproteins.com](http://www.scilproteins.com)